Concourse Financial Group Securities, Inc. Freeline Therapeutics Holdings PLC Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share
Q1 2023 May 15, 2023	BUY	$0.42 - $0.63 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.46 - $0.73 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.69 - $1.1 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.69 - $1.12 $0 - $0
Q1 2022 May 09, 2022	BUY	$0.92 - $2.03 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$1.97 - $3.45 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$3.04 - $8.9 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$8.15 - $13.9 $0 - $0
Q1 2021 May 13, 2021	BUY	$12.3 - $18.2 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$14.94 - $18.3 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$15.45 - $18.12 $0 - $0

Others Institutions Holding FRLN

# of Institutions

Shares Held

30.1K

Call Options Held

Put Options Held

Odey Asset Management Group LTD London, X0

30.1K
Shares

$0
0.0% of portfolio

View Full List

About Freeline Therapeutics Holdings plc

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

More about FRLN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account